Author Archives: Millie Nelson

Sartorius inks deal for virus clearance center in Scotland

Sartorius has bolstered its virus clearance R&D capabilities in Lanarkshire, Scotland after signing a 15-year lease. The deal, of which financial details have not been disclosed, sees German life sciences firm Sartorius take over more than 8,500 square-feet within Maxim 3 at the Eurocentral park for various research. Lonza already has a presence in Glasgow, Scotland with a competence center for bioanalytics and a small team of experts for virus clearance services following its acquisition of BioOutsource in 2015. “This…

Lonza to expand DP capabilities in Switzerland

Lonza will invest in additional drug product manufacturing capabilities in Switzerland to accelerate existing service offerings in Basel and Visp. The expansion will see contract development manufacturing organization (CDMO) Lonza install an aseptic fill-finish line in Stein, Switzerland and expand drug product services in Basel and Visp. “We constantly assess our assets and invest in developing and installing new capacity and technology to meet the market demand in biologics,” Peter Droc, head of drug product services at Lonza told BioProcess…

Chinese CDMO market growing rapidly despite talent shortage, says Lonza

Lonza says its presence in China is growing despite a short-term talent shortage in the industry. “The Chinese pharma market is big and growing very quickly [with] a lot of molecules that are in development,” Lonza’s general manager of China, Hong Pan, tells BioProcess Insider. “China was very generically driven but more companies are putting their money into innovative pharma. The added growth is due to a few factors, [such as] the increased wealth of the population. People are getting…

Moderna and AbCellera join forces to develop antibody therapies

Moderna’s mRNA technology platform will be combined with AbCellera’s AI-powered antibody discovery platform to develop mRNA-encoded antibody therapeutics. The multi-year deal, of which financial details have not been disclosed, will see Moderna use AbCellera’s antibody discovering platform to search and examine natural immune responses to identify therapeutic antibodies against up to six targets. AbCellera’s platform will be combined with Moderna’s messenger RNA (mRNA) technology platform with a shared aim of accelerating the development of mRNA-encoded antibody therapeutics. Under the terms…

CEVEC and UCB ink AAV manufacturing agreement

UCB will use CEVEC’S adeno-associated virus (AAV) vector manufacturing technology platform to research, develop and produce AAV gene therapy products. Under the terms of the agreement, CEVEC Pharmaceuticals will grant UCB the non-exclusive rights to its ELEVECTA technology to research, develop, and manufacture Adeno-Associated Virus (AAV) vectors for gene therapy applications. The deal also provides UCB with the option to obtain licenses for use of the ELEVECTA producer cell lines in commercial production of potential AAV gene therapy candidates, and…

Thermo Fisher invests $154m to expand NC plant

Thermo Fisher will increase manufacturing capacity for fill-finish services at its Greenville, US facility with an $154 million investment.  Bioprocess vendor Thermo Fisher Scientific has unveiled plans to bolster its manufacturing capacity for sterile liquid and lyophilized filling, pre-filled syringes, and solid dose continuous manufacturing at its Greenville, North Caroline facility. The $154 million investment is not part of the firm’s recent $600 million CAPEX plan, which had the trade press salivating in March.  “Our continued growth in capabilities and capacity at our Greenville site has enabled us to support our clients’ needs and the patients they serve,” a…

AGC Bio bolsters pDNA and mRNA capacity with German plant expansion

CDMO AGC Bio will expand its Heidelberg, Germany facility to increase its manufacturing capacities for customer pDNA and mRNA projects. The expansion, of which financial details have not been disclosed, sees contract development manufacturing organization (CDMO) AGC Biologics boost its current production capacity for plasmid-DNA (pDNA) and messenger RNA (mRNA) by adding an additional manufacturing line. The Heidelberg expansion will also include additional warehouse capacity, a cleanroom for mRNA development and production, and a process development lab for microbial protein…

CureVac drops CDMOs but continues COVID-19 vaccine development

CureVac has terminated contracts with two of its CDMOs – Wacker and Celonic – after demand for potential COVID-19 vaccine diminishes. However, the firm remains positive future clinical trials will go ahead. The German biotech entered the COVID-19 vaccine race in March 2020 and began creating mRNA COVID-19 candidate, CVnCoV. The firm quickly struck deals with various contract development manufacturing organizations (CDMOs) such as Novartis, Bayer, Rentschler, GSK, Wacker and Celonic to support production of the candidate. However, just a few…

Affinia strikes strategic AAV manufacturing deal with Lonza

Affinia has signed a multi-year agreement with CDMO Lonza to make gene therapy candidates targeting cancer and neurological disorders. Swiss contract development manufacturing organization (CDMO) Lonza will provide manufacturing services for Affinia Therapeutics for two of its gene therapy candidates targeting metachromatic leukodystrophy (MLD), a rare neurodegenerative disease, and brain metastases secondary to human epidermal growth factor receptor 2 positive (HER2+) breast cancer. Both candidates are based on the firm’s lead adeno-associated virus (AAV) vector, Anc80L65. Anc80L65-ARSA aims to treat…

Ins & Outs: Genezen new CEO to lead transition into full service CDMO

Ray Kaczmarek, the new CEO of Genezen, figuratively sat down with BioProcess Insider to discuss his strategy and aims for the firm. Sit back, relax, and enjoy this week’s Ins and outs. Kaczmarek has spent the past 20 years in pharmaceutical and biotechnology manufacturing, as well as supply chain operations, serving in senior roles at Trilink Biotechnologies, Nitto Avecia Pharma Services, and Pacira Biosciences. His latest career move takes him to contract development manufacturing organization (CDMO) Genezen, where he serves as…